Mesenteric Fat Lipolysis Mediates Obesity-Associated Hepatic Steatosis and Insulin Resistance
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Hepatic steatosis and insulin resistance are among the most prevalent metabolic disorders and are tightly associated with obesity and type 2 diabetes. However, the underlying mechanisms linking obesity to hepatic lipid accumulation and insulin resistance are incompletely understood. Glycoprotein 130 (gp130) is the common signal transducer of all interleukin 6 (IL-6) cytokines. We provide evidence that gp130-mediated adipose tissue lipolysis promotes hepatic steatosis and insulin resistance. In obese mice, adipocyte-specific gp130 deletion reduced basal lipolysis and enhanced insulin’s ability to suppress lipolysis from mesenteric but not epididymal adipocytes. Consistently, free fatty acid levels were reduced in portal but not in systemic circulation of obese knockout mice. Of note, adipocyte-specific gp130 knockout mice were protected from high-fat diet–induced hepatic steatosis as well as from insulin resistance. In humans, omental but not subcutaneous IL-6 mRNA expression correlated positively with liver lipid accumulation (r = 0.31, P < 0.05) and negatively with hyperinsulinemic-euglycemic clamp glucose infusion rate (r = −0.28, P < 0.05). The results show that IL-6 cytokine-induced lipolysis may be restricted to mesenteric white adipose tissue and that it contributes to hepatic insulin resistance and steatosis. Therefore, blocking IL-6 cytokine signaling in (mesenteric) adipocytes may be a novel approach to blunting detrimental fat-liver crosstalk in obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“Accordingly, in humans, up to 59% of FFA bound in liver TGs may arise from plasma FFA (40).”
BackgroundNguyen, M. T. A., Favelyukis, S., Nguyen, A.-K., Reichart, D., Scott, P. A., Jenn, A., Liu-Bryan, R., Glass, C. K., Neels, J. G., & Olefsky, J. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706762200 · Cited by 1,035
Splanchnic lipolysis in human obesity
Nielsen, S., Guo, Z., Johnson, C. M., Hensrud, D. D., & Jensen, M. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21047 · Cited by 933
Interleukin-6 stimulates lipolysis and fat oxidation in humans
van Hall, G., Steensberg, A., Sacchetti, M., Fischer, C., Keller, C., Schjerling, P., Hiscock, N., Møller, K., Saltin, B., Febbraio, M. A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021687 · Cited by 767 · cited 1×
“Indeed, IL-6 was shown to induce lipolysis in vivo and in vitro (14,15), and a recent study suggested that IL-6 promotes hepatic insulin resistance indirectly through increased free fatty acid (FFA) release from AT in rodents (16).”
BackgroundPerry, R. J., Camporez, J.-P. G., Kursawe, R., Titchenell, P. M., Zhang, D., Perry, C. J., Jurczak, M. J., Abudukadier, A., Han, M. S., Zhang, X.-M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.012 · Cited by 719 · cited 6×
“Indeed, IL-6 was shown to induce lipolysis in vivo and in vitro (14,15), and a recent study suggested that IL-6 promotes hepatic insulin resistance indirectly through increased free fatty acid (FFA) release from AT in rodents (16).”
BackgroundInfluentialSenn, J. J., Klover, P. J., Nowak, I. A., Zimmers, T. A., Koniaris, L. G., Furlanetto, R. W., & Mooney, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210689200 · Cited by 620 · cited 1×
“In contrast, mRNA expression of SOCS3, which can be induced in the liver by IL-6, thereby promoting hepatic insulin resistance (38), was similar in HFD-fed gp130 and control littermates (1.”
ResultInterleukin-6 and its receptors: a highly regulated and dynamic system
Wolf, J., Rose-John, S., & Garbers, C. (2014) · Cytokine · doi:10.1016/j.cyto.2014.05.024 · Cited by 618 · cited 2×
“Although we are aware that knockout of gp130 in adipocytes affects the signaling pathway of all members of the IL-6 cytokines, the mouse model still seems adequate to investigate our hypothesis because the mIL-6R is not expressed in adipocytes (7), precluding cell-specific depletion of IL-6 signaling in adipocytes sim…”
BackgroundLam, Y. Y., Ha, C. W. Y., Campbell, C. R., Mitchell, A. J., Dinudom, A., Oscarsson, J., Cook, D. I., Hunt, N. H., Caterson, I. D., Holmes, A. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034233 · Cited by 604 · cited 2×
“obesity-induced IL-6 increase in other studies was higher in mesenteric fat than in other adipose depots (17,18), suggesting that IL-6–induced AT lipolysis plays a distinct role in visceral fat.”
BackgroundIncreased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis
Wieckowska, A., Papouchado, B. G., Li, Z., Lopez, R., Zein, N. N., & Feldstein, A. E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01774.x · Cited by 597
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“, 1990), which may be driven in part by interleukin6 (IL-6) (Wueest et al., 2016).”
BackgroundInfluentialNonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
Bello-Chavolla, O. Y., Almeda-Valdes, P., Gomez-Velasco, D., Viveros-Ruiz, T., Cruz-Bautista, I., Romo-Romo, A., Sánchez-Lázaro, D., Meza-Oviedo, D., Vargas-Vázquez, A., Campos, O. A., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0883 · Cited by 664
Luukkonen, P. K., Sädevirta, S., Zhou, Y., Kayser, B., Ali, A., Ahonen, L., Lallukka, S., Pelloux, V., Gaggini, M., Jian, C., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0071 · Cited by 428
“In mice, a high-fat diet increases adipose tissue lipolysis (6).”
BackgroundWhite adipose tissue dysfunction in obesity and aging
Reyes-Farias, M., Fos-Domenech, J., Serra, D., Herrero, L., & Sánchez-Infantes, D. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114723 · Cited by 250
Pérez-Matute, P., Íñiguez, M., de Toro, M., Recio-Fernández, E., & Oteo, J. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-64961-x · Cited by 42
Wu, Z., Xu, J., Tan, J., Song, Y., Liu, L., Zhang, F., Zhang, Y., Li, X., Chi, Y., & Liu, Y. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14232 · Cited by 38
Metadata
- Authors
- Wueest, S., Item, F., Lucchini, F. C., Challa, T. D., Müller, W., Blüher, M., & Konrad, D.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-09-17
- Volume
- 65
- Issue
- 1
- Pages
- 140-148
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2201783325
- Cited by
- 96
- References
- 17
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.